Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.04% | 33.84% | 9.51% | -9.12% | -102.36% |
| Total Depreciation and Amortization | -11.80% | -2.07% | -2.03% | -9.34% | 59.66% |
| Total Amortization of Deferred Charges | 1.92% | 17.45% | -- | -- | -100.00% |
| Total Other Non-Cash Items | 13.07% | 11.44% | -16.45% | -0.32% | 100.18% |
| Change in Net Operating Assets | 40.98% | -274.49% | 83,000.00% | -99.96% | -73.63% |
| Cash from Operations | -12.92% | 16.55% | 17.90% | -44.38% | 47.21% |
| Capital Expenditure | -- | 100.00% | -31.25% | 93.52% | 79.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -31.25% | 93.52% | 79.67% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.77% | -146.86% | 246.16% | -43.27% | -19.14% |